Femasys Inc. (FEMY)
NASDAQ: FEMY · Real-Time Price · USD
1.080
+0.020 (1.89%)
At close: May 12, 2025, 4:00 PM
1.130
+0.050 (4.63%)
After-hours: May 12, 2025, 7:53 PM EDT
Femasys Revenue
Femasys had revenue of $341.26K in the quarter ending March 31, 2025, with 25.86% growth. This brings the company's revenue in the last twelve months to $1.70M, up 61.97% year-over-year. In the year 2024, Femasys had annual revenue of $1.63M with 51.97% growth.
Revenue (ttm)
$1.70M
Revenue Growth
+61.97%
P/S Ratio
14.42
Revenue / Employee
$23,933
Employees
71
Market Cap
29.32M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
FEMY News
- 4 days ago - Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations - GlobeNewsWire
- 7 weeks ago - Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain - GlobeNewsWire
- 2 months ago - Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach - GlobeNewsWire
- 2 months ago - Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials - GlobeNewsWire
- 3 months ago - Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices - GlobeNewsWire
- 3 months ago - Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control - GlobeNewsWire